Barclays
RVMD icon

Barclays’s Revolution Medicines RVMD Stock Holding History

Barclays’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,000
Closed -$806K – 5243
2024
Q1 		$806K Buy
+25,000
New +$741K ﹤0.01% 3284

Other funds holding RVMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Barclays's RVMD Position: Q3 2026 in Review

Barclays reduced its Revolution Medicines (RVMD) stake by 2.3% in Q3 2026, selling an estimated $513K and leaving 108,588 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1196.

Barclays first reported a position in RVMD in Q1 2022 and has held it in 19 quarters since. The position peaked at $37.3M in Q1 2026. 577 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • Barclays held 108,588 shares of Revolution Medicines worth $22.3M as of Q3 2026.
  • Barclays sold 2,590 Revolution Medicines shares in Q3 2026, an estimated $513K.
  • Revolution Medicines made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1196 holding.
  • Barclays first reported a position in Revolution Medicines in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Revolution Medicines position peaked at $37.3M in Q1 2026.
  • 577 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.